Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

Cancer Medicine

Volumn 4, Issue 7, 2015, Pages 995-1002

  Casado, Luis Felipe ^a,b   García Gutiérrez, José Valentín ^a,c   Massagué, Isabel ^a,d   Giraldo, Pilar ^a,e   Pérez Encinas, Manuel ^a,f   de Paz, Raquel ^a,g   Martínez López, Joaquín ^a,h   Bautista, Guiomar ^a,i   Osorio, Santiago ^a,j   Requena, María José ^a,k   Palomera, Luis ^a,l   Peñarrubia, María Jesús ^a,m   Calle, Carmen ^a,n   Hernández Rivas, José Ángel ^a,o   Burgaleta, Carmen ^a,p   Maestro, Begoña ^a,q   García Ormeña, Nuria ^a,b   Steegmann, Juan Luis ^a,q  

^a Registro Español De Investigación Y Tratamiento De Leucemia Mieloide Cronica RELMC   (Spain)

^b HOSPITAL VIRGEN DE LA SALUD   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^f Instituto de Salud Carlos III   (Spain)

^g HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k HOSPITAL SEVERO OCHOA   (Spain)

^l HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^m HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

ⁿ HOSPITAL GENERAL UNIVERSITARIO DE CIUDAD REAL   (Spain)

^o HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^p HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^q HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

more..

Author keywords

BCR ABL ABL ratio; Chronic myeloid leukemia; Dasatinib; Imatinib; Nilotinib

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER REGISTRY; CHRONIC MYELOID LEUKEMIA; CLINICAL PRACTICE; DRUG CHOICE; DRUG CLASSIFICATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SPAIN; TREATMENT DURATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MIDDLE AGED; MORTALITY; ONCOGENE; RETREATMENT; TIME FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG SUBSTITUTION; FEMALE; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ABL; HUMANS; IMATINIB MESYLATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RETREATMENT; RETROSPECTIVE STUDIES; TIME FACTORS; TRANSCRIPTION, GENETIC; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85006200849     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.440     Document Type: Article

References (19)

1. Hasford, J., M. Pfirrmann, and A. Hochhaus. 2005. How long will chronic myeloid leukemia patients treated with imatinib mesylate live? Leukemia 19:497-499.
2. Sokal, J. E., E. B. Cox, M. Baccarani, S. Tura, G. A. Gomez, J. E. Robertson, et al. 1984. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63:789-799.
3. Hasford, J., M. Pfirrmann, P. Shepherd, J. Guilhot, R. Hehlmann, F. X. Mahon, et al. 2005. The impact of the combination of baseline risk group and cytogenetic response on the survival of patients with chronic myeloid leukemia treated with interferon alpha. Haematologica 90:335-340.
4. Hasford, J., M. Baccarani, V. Hoffmann, J. Guilhot, S. Saussele, G. Rosti, et al. 2011. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood 118:686-692.
5. Marin, D., A. R. Ibrahim, C. Lucas, G. Gerrard, L. Wang, R. M. Szydlo, et al. 2012. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J. Clin. Oncol. 30:232-238.
6. Jabbour, E., H. M. Kantarjian, G. Saglio, J. L. Steegmann, N. P. Shah, C. Boque, et al. 2014. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). Blood 123:494-500.
7. Hughes, T. P., G. Saglio, H. M. Kantarjian, F. Guilhot, D. Niederwieser, G. Rosti, et al. 2014. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 123:1353-1360.
8. Brummendorf, T. H., H. M. Kantarjian, C. Gambacorti-Passerini, F. Guilhot, L. Akard, V. Doshi, et al. 2012. Assessment of early molecular response as a predictor of long-term clinical outcomes in the phase 3 BELA study. ASH Annual Meeting Abstracts. 120:69.
9. Guilhot, J., M. Baccarani, R. E. Clark, F. Cervantes, F. Guilhot, A. Hochhaus, et al. 2012. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. Blood 119:5963-5971.
10. Hughes, T., M. Deininger, A. Hochhaus, S. Branford, J. Radich, J. Kaeda, et al. 2006. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108:28-37.
11. Sacha, T., A. Hochhaus, B. Hanfstein, M. C. Muller, Z. Rudzki, J Czopek, et al. 2003. ABL-kinase domain point mutation as a cause of imatinib (STI571) resistance in CML patient who progress to myeloid blast crisis. Leuk. Res. 27:1163-1166.
12. O'Brien, S., E. Berman, J. O. Moore, J. Pinilla-Ibarz, J. P Radich, P. J. Shami, et al. 2011. NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia. J. Natl. Compr. Canc. Netw. 9(Suppl. 2):S1-S25.
13. Baccarani, M., M. W. Deininger, G. Rosti, A. Hochhaus, S. Soverini, J. F. Apperley, et al. 2013. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872-884.
14. Baccarani, M., G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, et al. 2006. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108:1809-1820.
15. Baccarani, M., J. Cortes, F. Pane, D. Niederwieser, G. Saglio, J. Apperley, et al. 2009. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J. Clin. Oncol. 27:6041-6051.
16. Yeung, D. T., M. P. Osborn, D. L. White, S. Branford, M. Kornhauser, C. Slader, et al. 2012. Early switch to nilotinib does not overcome the adverse outcome for CML patients failing to achieve early molecular response on imatinib, despite excellent overall outcomes in the TIDEL II trial. ASH Annual Meeting Abstracts. 120:3771.
17. Hanfstein, B., M. C. Muller, R. Hehlmann, P. Erben, M. Lauseker, A. Fabarius, et al. 2012. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096-2102.
18. Hochhaus, A., S. G. O'Brien, F. Guilhot, B. J. Druker, S. Branford, L. Foroni, et al. 2009. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054-1061.
19. Nazha, A., H. Kantarjian, P. Jain, C. Romo, E. Jabbour, A. Quintas-Cardama, et al. 2013. Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months. Haematologica 98:1686-1688.